All News

My multiple myeloma nurse case manager sat in on every appointment, helped me appeal an insurance denial and made sure I never felt like just a number.

Dr. Doured Daghistani discusses how childhood cancer treatment, survivorship care and immunotherapy have evolved this Childhood Cancer Awareness Month.

My daughter was 27 when breast cancer forced a decision about her fertility in days, and I keep thinking about the young women who can't afford that choice.

Explore how personalized treatment, immunotherapy, AI and other advances are transforming cancer care, with insights from Dr. Manmeet Ahluwalia.

Dr. Doured Daghistani explains how pediatric oncology is shifting toward reducing long-term side effects as childhood cancer survival rates rise.

Two and a half years into cancer treatment, my nurse Jenny Gnoza still greets me with a smile, steadies my nerves and finds the vein everyone else misses.

AI is changing breast cancer screening, helping doctors detect cancer and predict future risk. Learn what AI mammography means for patients.

FDA grants accelerated approval to camizestrant for certain advanced breast cancers with ESR1 mutations, offering a new treatment option.

Cancer can change, hide from the immune system and escape treatment, making effective therapy about more than targeting cancer cells alone.

Learn what patients should know about thyroid cancer treatment, including surgery, radioactive iodine, surveillance, hormone replacement and new advances.

Jen Christensen, RN, BSN, MSN, of City of Hope Orange County, brings deep personal experience with cancer loss to her role as a nurse manager, combining clinical excellence with compassionate, family-centered care.

Former NFL linebacker Chris Draft honors his late wife Keasha by advocating for lung cancer research and equitable access to care.

Four breast cancer treatments are awaiting FDA decisions, with two due before the end of 2026. Here's what's under review, what the data show and what it means.

T-cell engagers and other cellular therapies could help the immune system recognize and target lung cancer, including small cell lung cancer.

NEJM-published phase 1/2 data show RASONQUE achieved a 42% response rate and 89% disease control in RAS mutant metastatic lung cancer.

In the phase 3 CERVINO trial, etentamig improved response rates and progression-free survival compared with standard therapies in patients with relapsed/refractory multiple myeloma.

Gail Fackler reflected on her husband Jim’s stage 4 small cell lung cancer diagnosis, the uncertainty they faced and the hope they found through a clinical trial.

Dr. Jenni Sheng discussed weight management after breast cancer, when medication may be considered and why survivorship care goes beyond cancer surveillance.

Brynn Forlizzi was just 15 when diagnosed with ovarian cancer. She shares 10 things that helped her navigate treatment while staying connected to her teenage life.

Lung cancer patient and her father, a cancer survivor and caregiver, share how community, hope and self-advocacy helped them through treatment.

The FDA approved six cancer drugs in August 2026, including a landmark pancreatic cancer pill. Here's what each approval means for patients and side effects.

Diagnosed with stage 2B lung cancer after a screening, Vicky found community and a new purpose through lung cancer advocacy.

T-cell engagers and antibody-drug conjugates are expanding the SCLC treatment landscape as researchers focus on improving responses and overcoming resistance.

Rob Lowe joins CURE Talks Cancer to share his grandmother's breast cancer journey, including the clinical trial that helped prolong her life after she was twice told to get her affairs in order.

Karyopharm submitted an FDA application seeking accelerated approval for XPOVIO plus ruxolitinib for patients with myelofibrosis.

Tagrisso plus Orpathys improved progression-free survival in patients with EGFR-mutated lung cancer and MET overexpression, SANOVO trial shows.

A cancer survivor reflects on body image, grief and emotional healing 12 years after treatment, and why healing doesn’t have to be perfect to be real.

The A-NEW study found that 42% of breast cancer survivors with slower early weight loss reached the 5% goal after Contrave was added.